Name | Caracemide |
---|---|
Synonyms |
N-Acetyl-N-(methylcarbamoyloxy)-N'-methylurea
N-((methylamino)carbonyl)-N-(((methylamino)carbonyl)oxy)acetamide |
Description | Caracemide (NSC-253272) is a novel anticancer agent derived from a hydroxamic acid. Caracemide inactivates R1 by covalent modification at the substrate-binding site and inhibits the enzyme ribonucleotide reductase of Escherichia coli. Caracemide has demonstrated to produce severe central nervous system (CNS) toxicity. Caracemide has a toxic metabolite, methylisocyanate (MIC), in vivo[1][2]. |
---|---|
Related Catalog | |
In Vivo | The mercapturic acid derivative AMCC was identified in urine rats following administration to rats of a single i.p. dose (6.6 mg/kg) of caracemide (NSC-253272)[1]. . |
References |
Density | 1.259g/cm3 |
---|---|
Molecular Formula | C6H11N3O4 |
Molecular Weight | 189.16900 |
Exact Mass | 189.07500 |
PSA | 87.74000 |
LogP | 0.22710 |
Index of Refraction | 1.479 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|